Long-Term Investments (Tables)

6 Months Ended

Jun. 30, 2022

Long Term Investment [Abstract]

Schedule of ownership percentages of investee

	Ownership percentage
	June 30,			December 31,			Accounting
Name of related party	2022			2021			treatments
Braingenesis Biotechnology Co., Ltd.		0.17	%		0.17	%	Cost Method
Genepharm Biotech Corporation		0.70	%		0.70	%	Cost Method
BioHopeKing Corporation		5.90	%		5.90	%	Cost Method
BioFirst Corporation		15.99	%		15.99	%	Equity Method
Rgene Corporation		31.62	%		31.62	%	Equity Method

Schedule of extent the investee relies

Name of related party	The extent the investee relies on the Company for its business
Braingenesis Biotechnology Co., Ltd.	No specific business relationship
Genepharm Biotech Corporation	No specific business relationship
BioHopeKing Corporation	Collaborating with the Company to develop and commercialize drugs
BioFirst Corporation	Collaborating with the Company to develop and commercialize drugs
Rgene Corporation	Collaborating with the Company to develop and commercialize drugs

Schedule of long-term investment

	June 30, 2022		December 31, 2021
	(Unaudited)
Non-marketable Cost Method Investments, net
Braingenesis Biotechnology Co., Ltd.	$	7,411	$	7,941
Genepharm Biotech Corporation		22,628		24,244
BioHopeKing Corporation		840,532		900,570
Sub total		870,571		932,755
Equity Method Investments, net
BioFirst Corporation		-		-
Rgene Corporation		-		-
Total	$	870,571	$	932,755

Schedule of balance sheet

	June 30, 2022			December 31, 2021
	(Unaudited)
Current Assets	$	2,065,236		$	2,205,669
Non-current Assets		877,630			959,454
Current Liabilities		3,501,538			2,909,703
Non-current Liabilities		113,615			32,522
Stockholders’ Equity (Deficit)		(672,287	)		222,898

	June 30, 2022			December 31, 2021
	(Unaudited)
Current Assets	$	1,227,904		$	73,452
Noncurrent Assets		330,231			374,423
Current Liabilities		2,221,846			1,934,786
Noncurrent Liabilities		-			-
Shareholders’ Deficit		(663,711	)		(1,486,911	)

Schedule of statements of operation

	Six Months Ended June 30,
	2022			2021
	(Unaudited)
Net sales	$	15,398		$	13,500
Gross profit		3,375			3,203
Net loss		(872,254	)		(465,704	)
Share of losses from investments accounted for using the equity method		-			(101,382	)

	Six Months Ended June 30,
	2022			2021
	(Unaudited)
Net sales	$	-		$	-
Gross Profit		-			-
Net loss		(295,517	)		(228,451	)
Share of loss from investments accounted for using the equity method		-			-

Schedule of equity investments

	Six Months Ended June 30,
	2022		2021
	(Unaudited)
Share of equity method investee losses	$	-	$	(101,382	)